R.B.
05-08-2006, 02:14 PM
Tamoxifen, ER, cyclin D1
I was having a tidy up and found this.
I also resolved the pasting issue. You have to change the posting option in set up to standard.
RB
http://www.arimidex.net/9370_13860_12_,_.aspx
“among the aggressive tumour characteristics more common among African-American women that white women were:
Estrogen- and progesterone-receptor status (positive or negative): A marker that has been tested and used to assess the likelihood of outcome regarding survival or cancer recurrence. Loss of estrogen and progesterone receptors on tumor cells (such as ER-negative or PR-negative status) is associated with poor clinical outcome. The odds of ER-negative tumors were nearly three times greater for African-American women than white women. The odds of having a PR-negative tumor were more than three times greater for African-American women than for white women.
Mitosis: Active cell division as determined by looking at the cancer cells under a microscope. Tumors with a high mitotic count are more aggressive. The odds of having a tumor with a high mitotic count were three times greater for African-American women than for white women.
P53: A protein product made by the p53 tumor-suppressor gene. When detected in large amounts, it often is associated with abnormal function of p53 and loss of cell-cycle control, which can lead to cancer. The odds of having a tumor with high p53 levels were twice as great for African-American women than for white women.
Cyclin E: A protein important for proper control of cell division. High levels of cyclin E can cause unrestrained cell division and is associated with poorer survival. The odds of having a tumor with high cyclin E levels was four times greater for African-American women than for white women.
Cyclin D: A protein important for proper control of cell division. High levels of cyclin D in many studies are associated with a better chance of survival. The odds of having a tumor with high cyclin D levels were half as great for African-American than for white women.
P16: A cell-division control protein. High levels of p16 can cause unrestrained cell division and have been associated with poorer survival in breast cancer. The odds of having a tumor with high p16 levels were nearly three times greater for African-American women than for white women.”
http://www.thelocal.se/article.php?ID=1999&date=20050901
A drug prescribed to more than half of all patients suffering from breast cancer can in some cases actually stimulate tumour growth and increase the likelihood of a relapse, Swedish researchers said on Thursday.
The drug, tamoxifen, has since the 1970s been widely prescribed to fight breast cancer since it has shown to counteract the cancer-promoting effects of estrogen in the breast by binding itself to the estrogen receptor in the cancerous cell, thus impeding tumour growth.
According to new research conducted at the Malmö University Hospital, UMAS, in southern Sweden however, the drug can have the opposite effect on certain types of tumours.
"The result shows that tamoxifen is a very efficient treatment for most patients. But for 15 percent of tumours that contain many copies of the cell-splitting gene cyclin D1 tamoxifen however appears to have the opposite effect," researcher Karin Jirström said in a statement.
The study conducted by Jirström and her colleagues was based on examinations of patients from southern Sweden who had been treated with the drug. It was recently published in the US medical journal Cancer Researcher.
I was having a tidy up and found this.
I also resolved the pasting issue. You have to change the posting option in set up to standard.
RB
http://www.arimidex.net/9370_13860_12_,_.aspx
“among the aggressive tumour characteristics more common among African-American women that white women were:
Estrogen- and progesterone-receptor status (positive or negative): A marker that has been tested and used to assess the likelihood of outcome regarding survival or cancer recurrence. Loss of estrogen and progesterone receptors on tumor cells (such as ER-negative or PR-negative status) is associated with poor clinical outcome. The odds of ER-negative tumors were nearly three times greater for African-American women than white women. The odds of having a PR-negative tumor were more than three times greater for African-American women than for white women.
Mitosis: Active cell division as determined by looking at the cancer cells under a microscope. Tumors with a high mitotic count are more aggressive. The odds of having a tumor with a high mitotic count were three times greater for African-American women than for white women.
P53: A protein product made by the p53 tumor-suppressor gene. When detected in large amounts, it often is associated with abnormal function of p53 and loss of cell-cycle control, which can lead to cancer. The odds of having a tumor with high p53 levels were twice as great for African-American women than for white women.
Cyclin E: A protein important for proper control of cell division. High levels of cyclin E can cause unrestrained cell division and is associated with poorer survival. The odds of having a tumor with high cyclin E levels was four times greater for African-American women than for white women.
Cyclin D: A protein important for proper control of cell division. High levels of cyclin D in many studies are associated with a better chance of survival. The odds of having a tumor with high cyclin D levels were half as great for African-American than for white women.
P16: A cell-division control protein. High levels of p16 can cause unrestrained cell division and have been associated with poorer survival in breast cancer. The odds of having a tumor with high p16 levels were nearly three times greater for African-American women than for white women.”
http://www.thelocal.se/article.php?ID=1999&date=20050901
A drug prescribed to more than half of all patients suffering from breast cancer can in some cases actually stimulate tumour growth and increase the likelihood of a relapse, Swedish researchers said on Thursday.
The drug, tamoxifen, has since the 1970s been widely prescribed to fight breast cancer since it has shown to counteract the cancer-promoting effects of estrogen in the breast by binding itself to the estrogen receptor in the cancerous cell, thus impeding tumour growth.
According to new research conducted at the Malmö University Hospital, UMAS, in southern Sweden however, the drug can have the opposite effect on certain types of tumours.
"The result shows that tamoxifen is a very efficient treatment for most patients. But for 15 percent of tumours that contain many copies of the cell-splitting gene cyclin D1 tamoxifen however appears to have the opposite effect," researcher Karin Jirström said in a statement.
The study conducted by Jirström and her colleagues was based on examinations of patients from southern Sweden who had been treated with the drug. It was recently published in the US medical journal Cancer Researcher.